Phebra Pharma

Executive Summary

Phebra Pharma is a privately held Australian manufacturer of critical care and sterile injectable medicines, with a portfolio of over 65 approved products serving hospital and healthcare markets domestically and internationally. Founded in 1993 and based in Lane Cove West, the company leverages a modern sterile manufacturing facility and a strong focus on quality to produce life-saving therapeutics across therapeutic areas including critical care, ophthalmology, cardiology, infectious diseases, and anesthesiology. Phebra's business model encompasses in-house development, contract manufacturing, and out-licensing partnerships, enabling it to expand its reach and product offerings. Despite being a commercial-stage private company with no disclosed funding or valuation, its established presence and diverse portfolio position it as a reliable supplier in niche hospital segments. The company's ability to maintain high-quality production and navigate regulatory requirements supports its competitive advantage in both Australian and export markets.

Upcoming Catalysts (preview)

• Q2 2026New Therapeutic Good Administration (TGA) approval for a critical care product70% success
• Q4 2026Expansion of sterile manufacturing capacity or new contract manufacturing agreement60% success
• Q3 2026Strategic partnership or out-licensing deal for ophthalmic or infectious disease product50% success